Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Poor Glycemic Control in Diabetes and the Risk of Incident Chronic Kidney Disease Even in the Absence of Albuminuria and Retinopathy: Atherosclerosis Risk in Communities (ARIC) Study

Poor Glycemic Control in Diabetes and the Risk of Incident Chronic Kidney Disease Even in the... Abstract Background Diabetic nephropathy is the leading cause of kidney failure in the United States. The extent to which an elevated glycated hemoglobin (HbA1c) concentration is associated with increased risk of chronic kidney disease (CKD) in the absence of albuminuria and retinopathy, the hallmarks of diabetic nephropathy, is uncertain. Methods Glycated hemoglobin concentration was measured in 1871 adults with diabetes mellitus followed up for 11 years in the Atherosclerosis Risk in Communities (ARIC) Study. Incident CKD was defined as an estimated glomerular filtration rate less than 60 mL/min/1.73 m2 after 6 years of follow-up or a kidney disease–related hospitalization. We categorized HbA1c concentrations into 4 clinically relevant categories. Albuminuria and retinopathy were measured midway through follow-up. Results Higher HbA1c concentrations were strongly associated with risk of CKD in models adjusted for demographic data, baseline glomerular filtration rate, and cardiovascular risk factors. Compared with HbA1c concentrations less than 6%, HbA1c concentrations of 6% to 7%, 7% to 8%, and greater than 8% were associated with adjusted relative hazard ratios (95% confidence intervals) of 1.4 (0.97-1.91), 2.5 (1.70-3.66), and 3.7 (2.76-4.90), respectively. Risk of CKD was higher in individuals with albuminuria and retinopathy, and the association between HbA1c concentration and incident CKD was observed even in participants without either abnormality: adjusted relative hazards, 1.46 (95% confidence intervals, 0.80-2.65), 1.17 (0.43-3.19), and 3.51 (1.67-7.40), respectively; Ptrend = .004. Conclusions We observed a positive association between HbA1c concentration and incident CKD that was strong, graded, independent of traditional risk factors, and present even in the absence of albuminuria and retinopathy. Hyperglycemia is an important indicator of risk of both diabetic nephropathy with albuminuria or retinopathy and of less specific forms of CKD. More than 26 million adults in the United States have chronic kidney disease (CKD), defined as decreased glomerular filtration rate (GFR) or increased urinary albumin excretion.1 Chronic kidney disease is associated with an increased risk of cardiovascular disease, morbidity, and mortality.2-7 As a major risk factor for cardiovascular disease, the National Kidney Foundation8 and the American Heart Association9 consider individuals with CKD to be in the highest-risk group for intervention. Diabetes mellitus (DM) is a leading cause of kidney failure in the United States, accounting for more than 40% of all incident cases of end-stage renal disease.10-12 Diabetes increases the risk for end-stage renal disease including disease that is a direct complication of DM and disease from causes other than DM.13 Diabetes is closely associated with microvascular disease and is often manifested as albuminuria or retinopathy,12,14 although approximately one-third of individuals with DM have decreased kidney function without either albuminuria or retinopathy.15 The increased concentration of glycated hemoglobin (HbA1c) is related to the development of microvascular disease in DM, and its reduction is at the center of the clinical management of hyperglycemia. Randomized studies in individuals with type 1 DM have shown that intensive treatment slows progression of microvascular complications (nephropathy, retinopathy, and neuropathy) and reduces the development and progression of microalbuminuria.16 The continuous relationship between HbA1c concentration and incidence of moderate CKD in individuals with DM, however, has not been well quantified to our knowledge. It is also unknown whether moderately elevated HbA1c concentrations predict a decline in kidney function in the absence of detectable microvascular disease as evidenced by albuminuria, retinopathy, or both. An improved understanding from observational data of the risks and consequences of DM in the absence of albuminuria and retinal damage is particularly important given recent concerns about stringent glycemic control and risk of death in certain individuals with DM who are at high risk.17 We examined the long-term independent association between moderately elevated concentrations of HbA1c and incident CKD in a population-based observational sample of adults with DM and evaluated the consistency of this association in those with and without albuminuria or retinopathy. Methods Study population Data were obtained from the Atherosclerosis Risk in Communities (ARIC) Study. This was a prospective biracial observational cohort of 15 792 individuals including 2187 with DM between the ages of 45 and 64. At baseline, their mean (SD) age was 54 (5.8) years; 55% were female, and 74% were white and 26% were African American. Individuals were recruited from a probability sample of 4 US communities: Forsyth County, North Carolina; Jackson, Mississippi; suburban Minneapolis, Minnesota; and Washington County, Maryland. Participants took part in examinations starting with a baseline visit (visit 1) between 1987 and 1989. Individuals underwent 3 follow-up examinations at approximately 3-year intervals at community clinics and answered annual follow-up telephone interviews between visits. Hospitalized events were ascertained continuously from ARIC Study inception through December 31, 2004. Details of the ARIC cohort have been published elsewhere.18 In the present study, we included all participants with DM at the second ARIC visit (visit 2, 1990-1992), the only visit in which the concentration of HbA1c was measured. Diabetes mellitus was defined as a fasting glucose concentration of 126 mg/dL or higher or a nonfasting glucose concentration of 200 mg/dL or higher (to convert to millimoles per liter, multiply by 0.0555), self-reported physician diagnosis of DM, or use of oral hypoglycemic medication or insulin. Of 1871 individuals, 1054 (56%) were identified on the basis of self-reported DM. A total of 1655 individuals (88%) were identified on the basis of elevated plasma glucose concentration: 1556 (83%) had a fasting plasma glucose concentration of at least 126 mg/dL, and 99 (7%) had a nonfasting glucose concentration of at least 200 mg/dL. Only 216 individuals (11.5%) reported having DM without also having an elevated plasma glucose concentration. We excluded 28 participants with missing HbA1c concentrations at visit 2 and 20 with missing serum creatinine levels at ARIC visit 1 or visit 2; 229 with an estimated GFR (eGFR) less than 60 mL/min/1.73 m2 at either ARIC visit 1 or visit 2; 3 participants who reported race as other than white or African American; and 8 African Americans from the Minnesota and Washington County study centers. Analyses are based on the remaining 1871 study participants. The study was approved by the institutional review boards at each of the sites, and written informed consent was obtained from all participants. Data collection Demographic and health behavior data, medical history, and measurements of height, weight, and blood pressure were obtained at each clinical examination. Blood was drawn at all clinic visits as described previously.19 Hemoglobin A1c was assayed from stored whole-blood samples from ARIC visit 2 using high-performance liquid chromatography instruments (Tosoh Bioscience Inc, South San Francisco, California) in a secondary reference laboratory of the National Glycohemoglobin Standardization Program at the University of Minnesota Medical Center, Fairview, and certified by the International Federation of Clinical Chemists.20-22 Measurements of HbA1c were available for 2159 of 2187 participants with DM (98.7%). The HbA1c concentrations were recalibrated to correct for an upward bias that was observed in a previous validation study comparing samples before and after long-term storage.21 A modified kinetic Jaffe method was used to measure the serum creatinine level at ARIC visits 2 and 4. The serum creatinine level was corrected for interlaboratory differences and indirectly calibrated to the Cleveland Clinic measurement by subtraction of 0.24 mg/dL (to convert to micromoles per liter, multiply by 88.4) from the visit 2 values and the addition of 0.18 mg/dL to the visit 4 values and then used to estimate GFR.3,23 The eGFR was calculated using the simplified Modification of Diet in Renal Disease equation developed at the Cleveland Clinic: eGFR = [186.3 × (serum creatinine [mg/dL]−1.154) × (age−0.203) × (0.742 if female) × (1.21 if African American)].24 Three seated blood pressure measurements were obtained by certified technicians using a random-zero sphygmomanometer after 5 minutes of rest. The mean of the second and third readings was recorded. Enzymatic methods were used to obtain total plasma cholesterol, high-density lipoprotein cholesterol, and triglyceride concentrations, and the low-density lipoprotein cholesterol concentration was calculated from these using the Friedewald equation.25 Smoking status was determined by self-reported cigarette smoking. Prevalent coronary heart disease (CHD) was defined as a history of physician-diagnosed myocardial infarction, electrocardiographic evidence of a previous myocardial infarction (presence of a major or minor Q-wave abnormality with T-wave or ST-segment abnormality), or self-reported previous coronary revascularization procedure. Self-reported medication use (eg, antihypertensive or antidiabetes agents) was verified by bottle inspection. Urinary albumin excretion was measured from a spot urine sample at ARIC visit 4 (1996-1998) as the ratio of albumin to creatinine (in milligrams per gram). Albuminuria was defined as an albumin to creatinine ratio of 30 mg/g or greater (which includes both the categories of microalbuminuria and macroalbuminuria). Retinography was conducted at ARIC visit 3 (1993-1995) in 1 randomly selected eye of each participant. A modification of the Airlie House classification system was used to grade lesions typical of diabetic retinopathy from a 45° color fundus photograph of 1 eye from each participant. Severity scores were assigned as follows: level 10, no retinopathy; level 20, minimal nonproliferative retinopathy (microaneurysms only or blot hemorrhages only); level 35, early nonproliferative retinopathy (microaneurysms and at least 1 of the following: venous loops, soft or hard exudate, and questionable intraretinal microvascular abnormalities or venous beading); levels 43 to 47, moderate to severe nonproliferative retinopathy (microaneurysms and at least 1 of the following: intraretinal microvascular abnormalities, venous beading, hemorrhages, and microaneurysms exceeding those of a standard photograph 2A); level 60 or higher, proliferative retinopathy. We considered a severity score of 20 or higher to indicate presence of retinopathy.26-28 Outcomes Incident CKD was defined as eGFR less than 60 mL/min/1.73 m2 at visit 4 (1996-1998, approximately 6 years after visit 2) or kidney disease noted during a hospitalization or death.29 All hospitalizations and deaths in ARIC participants were ascertained through review of medical records, annual follow-up interviews, and death certificates. Identification of hospital events was limited to those in acute-care hospitals and did not include events in nursing homes, psychiatric hospitals, or other locations. Deaths were recorded regardless of location, and death certificates were abstracted for both underlying and contributory causes of death. Hospitalizations identified through active surveillance and used to identify cases included the following: hospitalizations (discharges or deaths) coded using the International Classification of Diseases, Ninth Revision, for chronic renal disease (codes 581-583 or 585-588), hypertensive renal disease (code 403), hypertensive heart and renal disease (code 404), unspecified disorder of kidney and ureter (code 593.9), DM with renal manifestations (code 250.4), kidney transplantation, renal dialysis, or adjustment/fitting of catheter (code V42.0, V45.1, or V56), hemodialysis (code 39.95) or peritoneal dialysis (code 54.98), and without acute renal failure (codes 584, 586, 788.9, and 958.5) as the primary or secondary hospitalization code. Statistical analysis We categorized HbA1c concentrations into categories (<6%, 6%-7%, 7%-8%, or >8%) corresponding to current American Diabetes Association guideline categories.30 Baseline characteristics of the population were compared across CKD status and HbA1c concentration categories using χ2 test. Incidence rates of CKD during follow-up were compared across HbA1c concentration categories. Follow-up time was calculated from the time of the second ARIC examination to the first date of CKD diagnosis, defined as the earliest of either the fourth examination (if GFR decline was indicated) or the discharge date of a CKD-related hospitalization. Participants were censored at death, withdrawal from the study, or December 31, 2004, whichever occurred first. Adjusted hazard ratios and their 95% confidence intervals for the time to development of CKD were computed using Cox proportional hazards models after first testing the assumption of proportionality of hazards over time. Models were developed comparing participants by HbA1c concentration category and by continuous HbA1c measurements. The continuous association between HbA1c concentration and incident CKD was estimated from a Poisson regression model including a fourth-order polynomial for HbA1c adjusted to the incidence rate for a 60-year-old white man with a baseline eGFR of 90 mL/min/1.73 m2. Multivariate models included age, sex, race, study center, baseline eGFR, body mass index (calculated as weight in kilograms divided by height in meters squared), hypertension status, use of antihypertensive agents, prevalent CHD, smoking status, and low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride concentrations. Analyses were repeated after stratification by the presence of albuminuria at visit 4 and retinopathy at visit 3 in 1231 participants for whom these data were available. All statistical analyses were conducted using commercially available software (STATA version 9.2; StataCorp, College Station, Texas, or SAS version 9.1; SAS Institute, Inc, Cary, North Carolina). Results Among the 1871 participants, higher HbA1c concentrations were directly associated with female sex, African American race, higher eGFR, fasting glucose concentration, prevalent CHD, hypertension, use of antihypertensive or antidiabetes agents, body mass index, and triglyceride concentration (Table 1). Higher HbA1c concentration category also was associated with lower high-density lipoprotein cholesterol concentration. A total of 361 cases of incident CKD occurred during a mean follow-up of 11 years (incidence rate, 17.0 CKD cases per 1000 person-years). A total of 120 cases were identified on the basis of a follow-up eGFR of less than 60 mL/min/1.73 m2, and 292 cases were identified on the basis of a kidney-related hospitalization or death (51 individuals met both criteria). Figure 1 compares the cumulative risk of developing CKD by HbA1c concentration category. From lowest to highest category, 11.8%, 16.5%, 23.8%, and 31.3% of participants developed CKD during the study (P < .001, log-rank test). The incidence rate was progressively higher with a higher category of HbA1c (Table 2). Cases detected on the basis of decreased eGFR at visit 4 (6 years after the baseline HbA1c measurement) are indicated by the steeper rise in the cumulative incidence curve at this follow-up visit. The trend for higher risk of decreased kidney function remained after adjustment for age, sex, and race as shown by the graded association across the entire range of HbA1c concentrations (Figure 2, which caps HbA1c concentrations at an upper limit for the overall sample). The association between HbA1c and the risk of CKD remained after further adjustment for other CKD risk factors including study center, body mass index, hypertension, use of antihypertensive medications, prevalent CHD, smoking status, low-density and high-density cholesterol concentrations, and triglyceride concentration (Table 2). Individuals with HbA1c concentrations between 6% and 7%, between 7% and 8%, and greater than 8% had hazard ratios (95% confidence intervals) of 1.37 (0.97-1.91), 2.49 (1.70-3.66), and 3.67 (2.76-4.90), respectively, of progressing to incident CKD compared with individuals with DM and HbA1c concentrations of 6% or less. In analyses of HbA1c concentrations as a continuous risk factor, each 1% increase in HbA1c concentration was associated with a 31% higher risk of developing CKD. The association was observed for both components of the combined case definition of incident CKD, though the association was somewhat weaker in analyses limited to events detected by a decrease in eGFR at visit 4 (hazard ratios, 1.13; 95% confidence intervals, 1.03-1.25, per 1% increase in HbA1c concentration) than for kidney disease–related hospitalizations (1.33; 1.26-1.40, per 1% increase in HbA1c concentration). The association was not appreciably altered when controlling for total cholesterol concentration, white blood cell count, or use of angiotensin-converting enzyme inhibitors at baseline (results not shown). The association remained in analyses setting the time of incident CKD to the midpoint between the 2 visit dates for cases defined by a decrease in eGFR (results not shown). Individuals who had developed either albuminuria or retinopathy by visits 3 and 4, respectively (Table 3), were at much higher risk of CKD than those with neither abnormality. Of the 217 cases of incident CKD occurring in participants who had undergone both urinalysis and retinography, almost one-fourth developed in individuals with only retinopathy (24%; n = 52), half that in those with only albuminuria (13%; n = 28), and the remaining two-thirds developed in individuals with both complications (29.5%; n = 64) or neither complication (33.6%; n = 73). The association of HbA1c concentration with incident CKD, however, was similar across these subgroups. A hazard ratio of 1.27 (95% confidence interval, 1.08-1.51) for a 1% increase in HbA1c concentration was observed in those without either albuminuria or retinopathy, consistent with the overall observed hazard ratios. Also consistent with overall trends, the trend for higher risk of decreased kidney function remained within each stratum of abnormalities (those developing neither albuminuria nor retinopathy, only 1 complication, or both), after adjustment for age, sex, and race as shown by the graded association across the entire range of HbA1c concentrations (Figure 3), capping HbA1c concentration at an upper limit of the stratum-specific 95th percentiles. We found no statistically significant interactions between HbA1c concentration and any demographic characteristics. We observed higher risk associated with higher HbA1c concentration in analyses even after stratifying by sex, race, hypertension status, history of CHD, and DM treatment status (results not shown). Comment We observed a strong association between higher HbA1c concentrations and incidence of CKD in adults with DM. This association was independent of traditional CKD risk factors and was observed across the entire range of HbA1c concentrations examined. This is one of few prospective studies to examine the risk of incident CKD in a large biracial community-based cohort. We included all individuals with DM, used an HbA1c assay certified by international programs and used for more than 2 decades in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study,22 and observed participants on average for more than 11 years. Even in the absence of both modest amounts of albuminuria and retinopathy, 2 hallmarks of diabetic microvascular disease, the concentration of HbA1c was positively associated with incident CKD. Diabetic nephropathy is diagnosed in the presence of persistent albuminuria (>30 mg per 24 hours) equivalent to 30 mg/g (urinary albumin to creatinine ratio), diabetic retinopathy, and no evidence of other kidney or renal tract disease.14 These results, however, demonstrate the importance of identifying the risk of developing kidney disease in individuals with DM even in the absence of albuminuria or retinopathy. Sixty percent of individuals with type 2 DM and hypertension develop nephropathy.12 In adults with DM, 13% have a decreased eGFR and 64% have albuminuria.15 About 1.1 million adults older than 40 years have both type 2 DM and decreased eGFR. More than half of these adults (59%) do not have albuminuria, and an estimated 0.3 million do not have either albuminuria or retinopathy.15 In this population-based study, among the 217 cases of incident CKD occurring in participants who had undergone both urinary albumin measurements and retinography, one-third (n = 73; 33.6%) developed in individuals without albuminuria or retinopathy, nearly one-third (n = 64; 29.4%) developed in individuals with both albuminuria and retinopathy, and the remaining cases (80 cases [37%]) developed in individuals with albuminuria (28 cases [13%]) or retinopathy (52 cases [24%]). The Framingham Heart Study offspring cohort demonstrated an increased odds of developing incident CKD associated with abnormal glycemic status,31 and although we know that stringent glycemic control decreases the risk of DM complications, cardiovascular disease, and CKD progression,17,32,33 kidney pathology has been underexplored in individuals with type 2 DM.14 Findings from the Multiple Risk Factor Intervention Trial, a multicenter prospective cohort of men, showed that men with DM are at increased risk of end-stage renal disease from all causes and from causes other than DM.13 Although this study cannot address the specific pathophysiologic mechanisms relating elevated HbA1c concentrations to incident CKD, there are a number of biologically plausible explanations for observed associations, many potentially acting through damage to the glomerular basement membrane. Hemodynamic factors and advanced glycation end products also may have important roles in kidney disease progression in both individuals with and without DM.34-37 Evidence links glucose excursions,38 insulin resistance,39 and DM40,41 to decreased diurnal blood pressure decline (nondipping). Evidence also suggests that non-dippers with DM have poorer cardiovascular prognoses,38 more target organ damage,42 and sympathetic activation in diabetic nephropathy.43 In our analysis, adjusting for blood pressure and antihypertensive medication use did not change the association. We could not, however, account for intraindividual physiologic variation over time or diurnal variations in systemic pressure. Glycemia also may affect intrarenal pressure. Intraglomerular hypertension can contribute to progression of diabetic nephropathy even in the absence of systemic hypertension.34 The ARIC Study did not collect information on type of DM in participants. The age at first DM diagnosis was asked of ARIC participants at the ARIC visit 3 (3 years after visit 2, the baseline of these analyses). Among 773 participants having a diagnosis of DM at visit 2, the mean (SD) time from diagnosis to visit 2 was 10 (9) years. Only 43 (3.8% of 1134 asked) reported having DM diagnosed at age 30 years or younger, which suggests that few had type 1 DM. The present study is also limited by the lack of a direct measure of kidney function. Direct measurement of kidney function is impractical in large cohorts, and most studies have relied on serum creatinine–based estimates of GFR. Estimated GFR was based on single measurements of creatinine at 3 different visits (measurements at visits 1 and 2 to exclude prevalent cases and at visit 4 to define incident cases). The association of higher HbA1c concentrations and CKD was also observed in analyses limited to hospitalizations involving a kidney diagnosis. Approximately 20% of individuals classified as having DM according to our definition did not meet the American Diabetes Association criteria for DM in place at the time (fasting glucose concentration ≥140 mg/dL), and only approximately 40% of our sample was prescribed medications to treat DM. Because of these early cases of DM, there are many individuals with HbA1c concentrations in the normal range. Risks across HbA1c concentrations were consistent across all population subgroups and did not differ by DM treatment status. Because measurements for albuminuria were available only at visit 4, we could only exclude prevalent cases of CKD stage 3 or greater, and, therefore, our sample may include individuals with prevalent CKD stage 1 or 2 at baseline. Measurements of HbA1c and urinary albumin excretion and retinography were performed only once, at 3 different intervals (urinalysis at visit 4, retinography at visit 3, and HbA1c at visit 2). By relying on a single measurement taken to detect either albuminuria or retinopathy, some cases may be missed. Those individuals without albuminuria at visit 4 are unlikely to have had albuminuria 6 years earlier.44 Likewise, if damage was not detected on retinal images obtained at visit 3, it is unlikely that substantial damage was present at visit 2. Though specific findings of retinal damage may not be consistently observed over time, previous data from the ARIC Study found regression of identified damage to be uncommon in individuals with DM.45 As in any study such as this, there is potential for residual confounding owing to unmeasured or mismeasured variables. In summary, we observed a positive association between HbA1c concentration and incident CKD that was strong, graded, independent of traditional risk factors, and present even at mildly elevated concentrations of HbA1c. In this population-based setting, approximately one-third of CKD incidence occurred in the presence of both albuminuria and retinopathy and one-third occurred in the absence of both conditions. These data suggest that glycemic control is an important modifiable risk factor in the pathology of kidney disease in individuals with DM, both in the presence and absence of other microvascular damage. These results also suggest that urinary albumin screening alone may not be adequate for CKD detection in individuals with type 2 DM. Correspondence: Lori D. Bash, MPH, Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, 2024 E Monument St, Ste 2-604, Baltimore, MD 21201 (lbash@jhsph.edu). Accepted for Publication: May 19, 2008. Author Contributions: Ms Bash had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Selvin and Coresh. Acquisition of data: Selvin, Steffes, and Coresh. Analysis and interpretation of data: Bash, Selvin, and Astor. Drafting of the manuscript: Bash. Critical revision of the manuscript for important intellectual content: Bash, Selvin, Steffes, Coresh, and Astor. Statistical analysis: Bash, Selvin, and Astor. Obtained funding: Coresh. Administrative, technical, and material support: Bash, Steffes, and Coresh. Study supervision: Astor. Financial Disclosure: None reported. Funding/Support: This study was supported in part by grants 5R01-DK-076770-02, 5T32-HL-007024-33 (Ms Bash) and 5T32-RR-023253-02 (Ms Bash) from the National Institutes of Health. Additional Information: The ARIC Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022. Additional Contributions: The staff and participants of the ARIC Study made important contributions to our study. References 1. Coresh JSelvin EStevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298 (17) 2038- 2047PubMedGoogle ScholarCrossref 2. Manjunath GTighiouart HCoresh J et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003;63 (3) 1121- 1129PubMedGoogle ScholarCrossref 3. Manjunath GTighiouart HIbrahim H et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003;41 (1) 47- 55PubMedGoogle ScholarCrossref 4. Muntner PHe JHamm LLoria CWhelton PK Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002;13 (3) 745- 753PubMedGoogle Scholar 5. Fried LFShlipak MGCrump C et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003;41 (8) 1364- 1372PubMedGoogle ScholarCrossref 6. Henry RMKostense PJBos G et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 2002;62 (4) 1402- 1407PubMedGoogle ScholarCrossref 7. Wattanakit KCoresh JMuntner PMarsh JFolsom AR Cardiovascular risk among adults with chronic kidney disease, with or without prior myocardial infarction. J Am Coll Cardiol 2006;48 (6) 1183- 1189PubMedGoogle ScholarCrossref 8. Levey ASBeto JACoronado BE et al. National Kidney Foundation Task Force on Cardiovascular Disease, Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? what do we need to learn? where do we go from here? Am J Kidney Dis 1998;32 (5) 853- 906PubMedGoogle ScholarCrossref 9. Sarnak MJLevey ASSchoolwerth AC et al. American Heart Association Councils on Kidney In Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention, Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney In Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108 (17) 2154- 2169PubMedGoogle ScholarCrossref 10. Collins AJKasiske BHerzog C et al. United States Renal Data System, Excerpts from the United States renal data system 2004 annual data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2005;45 (1) ((suppl 1)) A5- A7PubMedGoogle ScholarCrossref 11. DuBose TD Jr American Society of Nephrology presidential address 2006. Chronic kidney disease as a public health threat: new strategy for a growing problem. J Am Soc Nephrol 2007;18 (4) 1038- 1045PubMedGoogle ScholarCrossref 12. So WYKong APMa RC et al. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care 2006;29 (9) 2046- 2052PubMedGoogle ScholarCrossref 13. Brancati FLWhelton PKRandall BLNeaton JDStamler JKlag MJ Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 1997;278 (23) 2069- 2074PubMedGoogle ScholarCrossref 14. Brenner BM Brenner & Rector's the Kidney. 7th ed. Philadelphia, PA WB Saunders Co2004; 15. Kramer HJNguyen QDCurhan GHsu CY Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003;289 (24) 3273- 3277PubMedGoogle ScholarCrossref 16. Diabetes Control and Complications Research Group, Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial. Kidney Int 1995;47 (6) 1703- 1720PubMedGoogle ScholarCrossref 17. NHLBI Communications Office, For safety, NHLBI changes intensive blood sugar treatment strategy in clinical trial of diabetes and cardiovascular disease. http://public.nhlbi.nih.gov/newsroom/home/GetPressRelease.aspx?id=2551. Accessed February 13, 2008 18. ARIC Investigators, The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol 1989;129 (4) 687- 702PubMedGoogle Scholar 19. Papp ACHatzakis HBracey AWu KK ARIC hemostasis study: I, development of a blood collection and processing system suitable for multicenter hemostatic studies. Thromb Haemost 1989;61 (1) 15- 19PubMedGoogle Scholar 20. Little RR Glycated hemoglobin standardization: National Glycohemoglobin Standardization Program (NGSP) perspective. Clin Chem Lab Med 2003;41 (9) 1191- 1198PubMedGoogle ScholarCrossref 21. Selvin ECoresh JJordahl JBoland LSteffes MW Stability of haemoglobin A1c (HbA1c) measurements from frozen whole blood samples stored for over a decade. Diabet Med 2005;22 (12) 1726- 1730PubMedGoogle ScholarCrossref 22. Steffes MCleary PGoldstein D et al. Hemoglobin A1c measurements over nearly two decades: sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study. Clin Chem 2005;51 (4) 753- 758PubMedGoogle ScholarCrossref 23. Coresh JAstor BCMcQuillan G et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 2002;39 (5) 920- 929PubMedGoogle ScholarCrossref 24. Levey ASBosch JPLewis JBGreene TRogers NRoth DModification of Diet in Renal Disease study group, A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130 (6) 461- 470PubMedGoogle ScholarCrossref 25. Friedewald WTLevy RIFredrickson DS Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18 (6) 499- 502PubMedGoogle Scholar 26. Klein RSharrett ARKlein BE et al. ARIC Group, The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the Atherosclerosis Risk in Communities Study. Ophthalmology 2002;109 (7) 1225- 1234PubMedGoogle ScholarCrossref 27. Sharrett ARHubbard LDCooper LS et al. Retinal arteriolar diameters and elevated blood pressure. the Atherosclerosis Risk in Communities Study. Am J Epidemiol 1999;150 (3) 263- 270PubMedGoogle ScholarCrossref 28. Hubbard LDBrothers RJKing WN et al. Methods for evaluation of retinal microvascular abnormalities associated with hypertension/sclerosis in the Atherosclerosis Risk in Communities Study. Ophthalmology 1999;106 (12) 2269- 2280PubMedGoogle ScholarCrossref 29. Shoham DAVupputuri SDiez Roux AV et al. Kidney disease in life-course socioeconomic context: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2007;49 (2) 217- 226PubMedGoogle ScholarCrossref 30. American Diabetes Association, Standards of medical care in diabetes: 2007. Diabetes Care 2007;30 ((suppl 1)) S4- S41PubMedGoogle ScholarCrossref 31. Fox CSLarson MGLeip EPMeigs JBWilson PWLevy D Glycemic status and development of kidney disease: the Framingham Heart Study. Diabetes Care 2005;28 (10) 2436- 2440PubMedGoogle ScholarCrossref 32. Wali RKHenrich WL Chronic kidney disease: a risk factor for cardiovascular disease. Cardiol Clin 2005;23 (3) 343- 362PubMedGoogle ScholarCrossref 33. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354(9178):602]. Lancet 1998;352 (9131) 837- 853PubMedGoogle ScholarCrossref 34. Forbes JMFukami KCooper ME Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes 2007;115 (2) 69- 84PubMedGoogle ScholarCrossref 35. Burns KD Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 2000;36 (3) 449- 467PubMedGoogle ScholarCrossref 36. Zhang SLFilep JGHohman TCTang SSIngelfinger JRChan JS Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells. Kidney Int 1999;55 (2) 454- 464PubMedGoogle ScholarCrossref 37. Huebschmann AGRegensteiner JGVlassara HReusch JE Diabetes and advanced glycoxidation end products. Diabetes Care 2006;29 (6) 1420- 1432PubMedGoogle ScholarCrossref 38. Pistrosch FReissmann EWildbrett JKoehler CHanefeld M Relationship between diurnal blood pressure variation and diurnal blood glucose levels in type 2 diabetic patients. Am J Hypertens 2007;20 (5) 541- 545PubMedGoogle ScholarCrossref 39. Afsar BSezer SElsurer ROzdemir FN Is HOMA index a predictor of nocturnal nondipping in hypertensives with newly diagnosed type 2 diabetes mellitus? Blood Press Monit 2007;12 (3) 133- 139PubMedGoogle ScholarCrossref 40. Cuspidi CMeani SLonati L et al. Short-term reproducibility of a non-dipping pattern in type 2 diabetic hypertensive patients. J Hypertens 2006;24 (4) 647- 653PubMedGoogle ScholarCrossref 41. Darcan SGoksen DMir S et al. Alterations of blood pressure in type 1 diabetic children and adolescents. Pediatr Nephrol 2006;21 (5) 672- 676PubMedGoogle ScholarCrossref 42. Izzedine HLaunay-Vacher VDeray G Abnormal blood pressure circadian rhythm: a target organ damage? Int J Cardiol 2006;107 (3) 343- 349PubMedGoogle ScholarCrossref 43. Tamura KTsurumi YSakai M et al. A possible relationship of nocturnal blood pressure variability with coronary artery disease in diabetic nephropathy. Clin Exp Hypertens 2007;29 (1) 31- 42PubMedGoogle ScholarCrossref 44. Caramori MLFioretto PMauer M Enhancing the predictive value of urinary albumin for diabetic nephropathy [published correction appears in J Am Soc Nephrol. 2006 Apr;17(4):1201]. J Am Soc Nephrol 2006;17 (2) 339- 352PubMedGoogle ScholarCrossref 45. Wong TYKlein RAmirul Islam FM et al. Three-year incidence and cumulative prevalence of retinopathy: the Atherosclerosis Risk in Communities Study. Am J Ophthalmol 2007;143 (6) 970- 976PubMedGoogle ScholarCrossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Internal Medicine American Medical Association

Poor Glycemic Control in Diabetes and the Risk of Incident Chronic Kidney Disease Even in the Absence of Albuminuria and Retinopathy: Atherosclerosis Risk in Communities (ARIC) Study

Download PDF
8 pages

Loading next page...
 
/lp/american-medical-association/poor-glycemic-control-in-diabetes-and-the-risk-of-incident-chronic-HWIiMta2Px

References (56)

Publisher
American Medical Association
Copyright
Copyright © 2008 American Medical Association. All Rights Reserved.
ISSN
0003-9926
eISSN
1538-3679
DOI
10.1001/archinte.168.22.2440
Publisher site
See Article on Publisher Site

Abstract

Abstract Background Diabetic nephropathy is the leading cause of kidney failure in the United States. The extent to which an elevated glycated hemoglobin (HbA1c) concentration is associated with increased risk of chronic kidney disease (CKD) in the absence of albuminuria and retinopathy, the hallmarks of diabetic nephropathy, is uncertain. Methods Glycated hemoglobin concentration was measured in 1871 adults with diabetes mellitus followed up for 11 years in the Atherosclerosis Risk in Communities (ARIC) Study. Incident CKD was defined as an estimated glomerular filtration rate less than 60 mL/min/1.73 m2 after 6 years of follow-up or a kidney disease–related hospitalization. We categorized HbA1c concentrations into 4 clinically relevant categories. Albuminuria and retinopathy were measured midway through follow-up. Results Higher HbA1c concentrations were strongly associated with risk of CKD in models adjusted for demographic data, baseline glomerular filtration rate, and cardiovascular risk factors. Compared with HbA1c concentrations less than 6%, HbA1c concentrations of 6% to 7%, 7% to 8%, and greater than 8% were associated with adjusted relative hazard ratios (95% confidence intervals) of 1.4 (0.97-1.91), 2.5 (1.70-3.66), and 3.7 (2.76-4.90), respectively. Risk of CKD was higher in individuals with albuminuria and retinopathy, and the association between HbA1c concentration and incident CKD was observed even in participants without either abnormality: adjusted relative hazards, 1.46 (95% confidence intervals, 0.80-2.65), 1.17 (0.43-3.19), and 3.51 (1.67-7.40), respectively; Ptrend = .004. Conclusions We observed a positive association between HbA1c concentration and incident CKD that was strong, graded, independent of traditional risk factors, and present even in the absence of albuminuria and retinopathy. Hyperglycemia is an important indicator of risk of both diabetic nephropathy with albuminuria or retinopathy and of less specific forms of CKD. More than 26 million adults in the United States have chronic kidney disease (CKD), defined as decreased glomerular filtration rate (GFR) or increased urinary albumin excretion.1 Chronic kidney disease is associated with an increased risk of cardiovascular disease, morbidity, and mortality.2-7 As a major risk factor for cardiovascular disease, the National Kidney Foundation8 and the American Heart Association9 consider individuals with CKD to be in the highest-risk group for intervention. Diabetes mellitus (DM) is a leading cause of kidney failure in the United States, accounting for more than 40% of all incident cases of end-stage renal disease.10-12 Diabetes increases the risk for end-stage renal disease including disease that is a direct complication of DM and disease from causes other than DM.13 Diabetes is closely associated with microvascular disease and is often manifested as albuminuria or retinopathy,12,14 although approximately one-third of individuals with DM have decreased kidney function without either albuminuria or retinopathy.15 The increased concentration of glycated hemoglobin (HbA1c) is related to the development of microvascular disease in DM, and its reduction is at the center of the clinical management of hyperglycemia. Randomized studies in individuals with type 1 DM have shown that intensive treatment slows progression of microvascular complications (nephropathy, retinopathy, and neuropathy) and reduces the development and progression of microalbuminuria.16 The continuous relationship between HbA1c concentration and incidence of moderate CKD in individuals with DM, however, has not been well quantified to our knowledge. It is also unknown whether moderately elevated HbA1c concentrations predict a decline in kidney function in the absence of detectable microvascular disease as evidenced by albuminuria, retinopathy, or both. An improved understanding from observational data of the risks and consequences of DM in the absence of albuminuria and retinal damage is particularly important given recent concerns about stringent glycemic control and risk of death in certain individuals with DM who are at high risk.17 We examined the long-term independent association between moderately elevated concentrations of HbA1c and incident CKD in a population-based observational sample of adults with DM and evaluated the consistency of this association in those with and without albuminuria or retinopathy. Methods Study population Data were obtained from the Atherosclerosis Risk in Communities (ARIC) Study. This was a prospective biracial observational cohort of 15 792 individuals including 2187 with DM between the ages of 45 and 64. At baseline, their mean (SD) age was 54 (5.8) years; 55% were female, and 74% were white and 26% were African American. Individuals were recruited from a probability sample of 4 US communities: Forsyth County, North Carolina; Jackson, Mississippi; suburban Minneapolis, Minnesota; and Washington County, Maryland. Participants took part in examinations starting with a baseline visit (visit 1) between 1987 and 1989. Individuals underwent 3 follow-up examinations at approximately 3-year intervals at community clinics and answered annual follow-up telephone interviews between visits. Hospitalized events were ascertained continuously from ARIC Study inception through December 31, 2004. Details of the ARIC cohort have been published elsewhere.18 In the present study, we included all participants with DM at the second ARIC visit (visit 2, 1990-1992), the only visit in which the concentration of HbA1c was measured. Diabetes mellitus was defined as a fasting glucose concentration of 126 mg/dL or higher or a nonfasting glucose concentration of 200 mg/dL or higher (to convert to millimoles per liter, multiply by 0.0555), self-reported physician diagnosis of DM, or use of oral hypoglycemic medication or insulin. Of 1871 individuals, 1054 (56%) were identified on the basis of self-reported DM. A total of 1655 individuals (88%) were identified on the basis of elevated plasma glucose concentration: 1556 (83%) had a fasting plasma glucose concentration of at least 126 mg/dL, and 99 (7%) had a nonfasting glucose concentration of at least 200 mg/dL. Only 216 individuals (11.5%) reported having DM without also having an elevated plasma glucose concentration. We excluded 28 participants with missing HbA1c concentrations at visit 2 and 20 with missing serum creatinine levels at ARIC visit 1 or visit 2; 229 with an estimated GFR (eGFR) less than 60 mL/min/1.73 m2 at either ARIC visit 1 or visit 2; 3 participants who reported race as other than white or African American; and 8 African Americans from the Minnesota and Washington County study centers. Analyses are based on the remaining 1871 study participants. The study was approved by the institutional review boards at each of the sites, and written informed consent was obtained from all participants. Data collection Demographic and health behavior data, medical history, and measurements of height, weight, and blood pressure were obtained at each clinical examination. Blood was drawn at all clinic visits as described previously.19 Hemoglobin A1c was assayed from stored whole-blood samples from ARIC visit 2 using high-performance liquid chromatography instruments (Tosoh Bioscience Inc, South San Francisco, California) in a secondary reference laboratory of the National Glycohemoglobin Standardization Program at the University of Minnesota Medical Center, Fairview, and certified by the International Federation of Clinical Chemists.20-22 Measurements of HbA1c were available for 2159 of 2187 participants with DM (98.7%). The HbA1c concentrations were recalibrated to correct for an upward bias that was observed in a previous validation study comparing samples before and after long-term storage.21 A modified kinetic Jaffe method was used to measure the serum creatinine level at ARIC visits 2 and 4. The serum creatinine level was corrected for interlaboratory differences and indirectly calibrated to the Cleveland Clinic measurement by subtraction of 0.24 mg/dL (to convert to micromoles per liter, multiply by 88.4) from the visit 2 values and the addition of 0.18 mg/dL to the visit 4 values and then used to estimate GFR.3,23 The eGFR was calculated using the simplified Modification of Diet in Renal Disease equation developed at the Cleveland Clinic: eGFR = [186.3 × (serum creatinine [mg/dL]−1.154) × (age−0.203) × (0.742 if female) × (1.21 if African American)].24 Three seated blood pressure measurements were obtained by certified technicians using a random-zero sphygmomanometer after 5 minutes of rest. The mean of the second and third readings was recorded. Enzymatic methods were used to obtain total plasma cholesterol, high-density lipoprotein cholesterol, and triglyceride concentrations, and the low-density lipoprotein cholesterol concentration was calculated from these using the Friedewald equation.25 Smoking status was determined by self-reported cigarette smoking. Prevalent coronary heart disease (CHD) was defined as a history of physician-diagnosed myocardial infarction, electrocardiographic evidence of a previous myocardial infarction (presence of a major or minor Q-wave abnormality with T-wave or ST-segment abnormality), or self-reported previous coronary revascularization procedure. Self-reported medication use (eg, antihypertensive or antidiabetes agents) was verified by bottle inspection. Urinary albumin excretion was measured from a spot urine sample at ARIC visit 4 (1996-1998) as the ratio of albumin to creatinine (in milligrams per gram). Albuminuria was defined as an albumin to creatinine ratio of 30 mg/g or greater (which includes both the categories of microalbuminuria and macroalbuminuria). Retinography was conducted at ARIC visit 3 (1993-1995) in 1 randomly selected eye of each participant. A modification of the Airlie House classification system was used to grade lesions typical of diabetic retinopathy from a 45° color fundus photograph of 1 eye from each participant. Severity scores were assigned as follows: level 10, no retinopathy; level 20, minimal nonproliferative retinopathy (microaneurysms only or blot hemorrhages only); level 35, early nonproliferative retinopathy (microaneurysms and at least 1 of the following: venous loops, soft or hard exudate, and questionable intraretinal microvascular abnormalities or venous beading); levels 43 to 47, moderate to severe nonproliferative retinopathy (microaneurysms and at least 1 of the following: intraretinal microvascular abnormalities, venous beading, hemorrhages, and microaneurysms exceeding those of a standard photograph 2A); level 60 or higher, proliferative retinopathy. We considered a severity score of 20 or higher to indicate presence of retinopathy.26-28 Outcomes Incident CKD was defined as eGFR less than 60 mL/min/1.73 m2 at visit 4 (1996-1998, approximately 6 years after visit 2) or kidney disease noted during a hospitalization or death.29 All hospitalizations and deaths in ARIC participants were ascertained through review of medical records, annual follow-up interviews, and death certificates. Identification of hospital events was limited to those in acute-care hospitals and did not include events in nursing homes, psychiatric hospitals, or other locations. Deaths were recorded regardless of location, and death certificates were abstracted for both underlying and contributory causes of death. Hospitalizations identified through active surveillance and used to identify cases included the following: hospitalizations (discharges or deaths) coded using the International Classification of Diseases, Ninth Revision, for chronic renal disease (codes 581-583 or 585-588), hypertensive renal disease (code 403), hypertensive heart and renal disease (code 404), unspecified disorder of kidney and ureter (code 593.9), DM with renal manifestations (code 250.4), kidney transplantation, renal dialysis, or adjustment/fitting of catheter (code V42.0, V45.1, or V56), hemodialysis (code 39.95) or peritoneal dialysis (code 54.98), and without acute renal failure (codes 584, 586, 788.9, and 958.5) as the primary or secondary hospitalization code. Statistical analysis We categorized HbA1c concentrations into categories (<6%, 6%-7%, 7%-8%, or >8%) corresponding to current American Diabetes Association guideline categories.30 Baseline characteristics of the population were compared across CKD status and HbA1c concentration categories using χ2 test. Incidence rates of CKD during follow-up were compared across HbA1c concentration categories. Follow-up time was calculated from the time of the second ARIC examination to the first date of CKD diagnosis, defined as the earliest of either the fourth examination (if GFR decline was indicated) or the discharge date of a CKD-related hospitalization. Participants were censored at death, withdrawal from the study, or December 31, 2004, whichever occurred first. Adjusted hazard ratios and their 95% confidence intervals for the time to development of CKD were computed using Cox proportional hazards models after first testing the assumption of proportionality of hazards over time. Models were developed comparing participants by HbA1c concentration category and by continuous HbA1c measurements. The continuous association between HbA1c concentration and incident CKD was estimated from a Poisson regression model including a fourth-order polynomial for HbA1c adjusted to the incidence rate for a 60-year-old white man with a baseline eGFR of 90 mL/min/1.73 m2. Multivariate models included age, sex, race, study center, baseline eGFR, body mass index (calculated as weight in kilograms divided by height in meters squared), hypertension status, use of antihypertensive agents, prevalent CHD, smoking status, and low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride concentrations. Analyses were repeated after stratification by the presence of albuminuria at visit 4 and retinopathy at visit 3 in 1231 participants for whom these data were available. All statistical analyses were conducted using commercially available software (STATA version 9.2; StataCorp, College Station, Texas, or SAS version 9.1; SAS Institute, Inc, Cary, North Carolina). Results Among the 1871 participants, higher HbA1c concentrations were directly associated with female sex, African American race, higher eGFR, fasting glucose concentration, prevalent CHD, hypertension, use of antihypertensive or antidiabetes agents, body mass index, and triglyceride concentration (Table 1). Higher HbA1c concentration category also was associated with lower high-density lipoprotein cholesterol concentration. A total of 361 cases of incident CKD occurred during a mean follow-up of 11 years (incidence rate, 17.0 CKD cases per 1000 person-years). A total of 120 cases were identified on the basis of a follow-up eGFR of less than 60 mL/min/1.73 m2, and 292 cases were identified on the basis of a kidney-related hospitalization or death (51 individuals met both criteria). Figure 1 compares the cumulative risk of developing CKD by HbA1c concentration category. From lowest to highest category, 11.8%, 16.5%, 23.8%, and 31.3% of participants developed CKD during the study (P < .001, log-rank test). The incidence rate was progressively higher with a higher category of HbA1c (Table 2). Cases detected on the basis of decreased eGFR at visit 4 (6 years after the baseline HbA1c measurement) are indicated by the steeper rise in the cumulative incidence curve at this follow-up visit. The trend for higher risk of decreased kidney function remained after adjustment for age, sex, and race as shown by the graded association across the entire range of HbA1c concentrations (Figure 2, which caps HbA1c concentrations at an upper limit for the overall sample). The association between HbA1c and the risk of CKD remained after further adjustment for other CKD risk factors including study center, body mass index, hypertension, use of antihypertensive medications, prevalent CHD, smoking status, low-density and high-density cholesterol concentrations, and triglyceride concentration (Table 2). Individuals with HbA1c concentrations between 6% and 7%, between 7% and 8%, and greater than 8% had hazard ratios (95% confidence intervals) of 1.37 (0.97-1.91), 2.49 (1.70-3.66), and 3.67 (2.76-4.90), respectively, of progressing to incident CKD compared with individuals with DM and HbA1c concentrations of 6% or less. In analyses of HbA1c concentrations as a continuous risk factor, each 1% increase in HbA1c concentration was associated with a 31% higher risk of developing CKD. The association was observed for both components of the combined case definition of incident CKD, though the association was somewhat weaker in analyses limited to events detected by a decrease in eGFR at visit 4 (hazard ratios, 1.13; 95% confidence intervals, 1.03-1.25, per 1% increase in HbA1c concentration) than for kidney disease–related hospitalizations (1.33; 1.26-1.40, per 1% increase in HbA1c concentration). The association was not appreciably altered when controlling for total cholesterol concentration, white blood cell count, or use of angiotensin-converting enzyme inhibitors at baseline (results not shown). The association remained in analyses setting the time of incident CKD to the midpoint between the 2 visit dates for cases defined by a decrease in eGFR (results not shown). Individuals who had developed either albuminuria or retinopathy by visits 3 and 4, respectively (Table 3), were at much higher risk of CKD than those with neither abnormality. Of the 217 cases of incident CKD occurring in participants who had undergone both urinalysis and retinography, almost one-fourth developed in individuals with only retinopathy (24%; n = 52), half that in those with only albuminuria (13%; n = 28), and the remaining two-thirds developed in individuals with both complications (29.5%; n = 64) or neither complication (33.6%; n = 73). The association of HbA1c concentration with incident CKD, however, was similar across these subgroups. A hazard ratio of 1.27 (95% confidence interval, 1.08-1.51) for a 1% increase in HbA1c concentration was observed in those without either albuminuria or retinopathy, consistent with the overall observed hazard ratios. Also consistent with overall trends, the trend for higher risk of decreased kidney function remained within each stratum of abnormalities (those developing neither albuminuria nor retinopathy, only 1 complication, or both), after adjustment for age, sex, and race as shown by the graded association across the entire range of HbA1c concentrations (Figure 3), capping HbA1c concentration at an upper limit of the stratum-specific 95th percentiles. We found no statistically significant interactions between HbA1c concentration and any demographic characteristics. We observed higher risk associated with higher HbA1c concentration in analyses even after stratifying by sex, race, hypertension status, history of CHD, and DM treatment status (results not shown). Comment We observed a strong association between higher HbA1c concentrations and incidence of CKD in adults with DM. This association was independent of traditional CKD risk factors and was observed across the entire range of HbA1c concentrations examined. This is one of few prospective studies to examine the risk of incident CKD in a large biracial community-based cohort. We included all individuals with DM, used an HbA1c assay certified by international programs and used for more than 2 decades in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study,22 and observed participants on average for more than 11 years. Even in the absence of both modest amounts of albuminuria and retinopathy, 2 hallmarks of diabetic microvascular disease, the concentration of HbA1c was positively associated with incident CKD. Diabetic nephropathy is diagnosed in the presence of persistent albuminuria (>30 mg per 24 hours) equivalent to 30 mg/g (urinary albumin to creatinine ratio), diabetic retinopathy, and no evidence of other kidney or renal tract disease.14 These results, however, demonstrate the importance of identifying the risk of developing kidney disease in individuals with DM even in the absence of albuminuria or retinopathy. Sixty percent of individuals with type 2 DM and hypertension develop nephropathy.12 In adults with DM, 13% have a decreased eGFR and 64% have albuminuria.15 About 1.1 million adults older than 40 years have both type 2 DM and decreased eGFR. More than half of these adults (59%) do not have albuminuria, and an estimated 0.3 million do not have either albuminuria or retinopathy.15 In this population-based study, among the 217 cases of incident CKD occurring in participants who had undergone both urinary albumin measurements and retinography, one-third (n = 73; 33.6%) developed in individuals without albuminuria or retinopathy, nearly one-third (n = 64; 29.4%) developed in individuals with both albuminuria and retinopathy, and the remaining cases (80 cases [37%]) developed in individuals with albuminuria (28 cases [13%]) or retinopathy (52 cases [24%]). The Framingham Heart Study offspring cohort demonstrated an increased odds of developing incident CKD associated with abnormal glycemic status,31 and although we know that stringent glycemic control decreases the risk of DM complications, cardiovascular disease, and CKD progression,17,32,33 kidney pathology has been underexplored in individuals with type 2 DM.14 Findings from the Multiple Risk Factor Intervention Trial, a multicenter prospective cohort of men, showed that men with DM are at increased risk of end-stage renal disease from all causes and from causes other than DM.13 Although this study cannot address the specific pathophysiologic mechanisms relating elevated HbA1c concentrations to incident CKD, there are a number of biologically plausible explanations for observed associations, many potentially acting through damage to the glomerular basement membrane. Hemodynamic factors and advanced glycation end products also may have important roles in kidney disease progression in both individuals with and without DM.34-37 Evidence links glucose excursions,38 insulin resistance,39 and DM40,41 to decreased diurnal blood pressure decline (nondipping). Evidence also suggests that non-dippers with DM have poorer cardiovascular prognoses,38 more target organ damage,42 and sympathetic activation in diabetic nephropathy.43 In our analysis, adjusting for blood pressure and antihypertensive medication use did not change the association. We could not, however, account for intraindividual physiologic variation over time or diurnal variations in systemic pressure. Glycemia also may affect intrarenal pressure. Intraglomerular hypertension can contribute to progression of diabetic nephropathy even in the absence of systemic hypertension.34 The ARIC Study did not collect information on type of DM in participants. The age at first DM diagnosis was asked of ARIC participants at the ARIC visit 3 (3 years after visit 2, the baseline of these analyses). Among 773 participants having a diagnosis of DM at visit 2, the mean (SD) time from diagnosis to visit 2 was 10 (9) years. Only 43 (3.8% of 1134 asked) reported having DM diagnosed at age 30 years or younger, which suggests that few had type 1 DM. The present study is also limited by the lack of a direct measure of kidney function. Direct measurement of kidney function is impractical in large cohorts, and most studies have relied on serum creatinine–based estimates of GFR. Estimated GFR was based on single measurements of creatinine at 3 different visits (measurements at visits 1 and 2 to exclude prevalent cases and at visit 4 to define incident cases). The association of higher HbA1c concentrations and CKD was also observed in analyses limited to hospitalizations involving a kidney diagnosis. Approximately 20% of individuals classified as having DM according to our definition did not meet the American Diabetes Association criteria for DM in place at the time (fasting glucose concentration ≥140 mg/dL), and only approximately 40% of our sample was prescribed medications to treat DM. Because of these early cases of DM, there are many individuals with HbA1c concentrations in the normal range. Risks across HbA1c concentrations were consistent across all population subgroups and did not differ by DM treatment status. Because measurements for albuminuria were available only at visit 4, we could only exclude prevalent cases of CKD stage 3 or greater, and, therefore, our sample may include individuals with prevalent CKD stage 1 or 2 at baseline. Measurements of HbA1c and urinary albumin excretion and retinography were performed only once, at 3 different intervals (urinalysis at visit 4, retinography at visit 3, and HbA1c at visit 2). By relying on a single measurement taken to detect either albuminuria or retinopathy, some cases may be missed. Those individuals without albuminuria at visit 4 are unlikely to have had albuminuria 6 years earlier.44 Likewise, if damage was not detected on retinal images obtained at visit 3, it is unlikely that substantial damage was present at visit 2. Though specific findings of retinal damage may not be consistently observed over time, previous data from the ARIC Study found regression of identified damage to be uncommon in individuals with DM.45 As in any study such as this, there is potential for residual confounding owing to unmeasured or mismeasured variables. In summary, we observed a positive association between HbA1c concentration and incident CKD that was strong, graded, independent of traditional risk factors, and present even at mildly elevated concentrations of HbA1c. In this population-based setting, approximately one-third of CKD incidence occurred in the presence of both albuminuria and retinopathy and one-third occurred in the absence of both conditions. These data suggest that glycemic control is an important modifiable risk factor in the pathology of kidney disease in individuals with DM, both in the presence and absence of other microvascular damage. These results also suggest that urinary albumin screening alone may not be adequate for CKD detection in individuals with type 2 DM. Correspondence: Lori D. Bash, MPH, Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, 2024 E Monument St, Ste 2-604, Baltimore, MD 21201 (lbash@jhsph.edu). Accepted for Publication: May 19, 2008. Author Contributions: Ms Bash had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Selvin and Coresh. Acquisition of data: Selvin, Steffes, and Coresh. Analysis and interpretation of data: Bash, Selvin, and Astor. Drafting of the manuscript: Bash. Critical revision of the manuscript for important intellectual content: Bash, Selvin, Steffes, Coresh, and Astor. Statistical analysis: Bash, Selvin, and Astor. Obtained funding: Coresh. Administrative, technical, and material support: Bash, Steffes, and Coresh. Study supervision: Astor. Financial Disclosure: None reported. Funding/Support: This study was supported in part by grants 5R01-DK-076770-02, 5T32-HL-007024-33 (Ms Bash) and 5T32-RR-023253-02 (Ms Bash) from the National Institutes of Health. Additional Information: The ARIC Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022. Additional Contributions: The staff and participants of the ARIC Study made important contributions to our study. References 1. Coresh JSelvin EStevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298 (17) 2038- 2047PubMedGoogle ScholarCrossref 2. Manjunath GTighiouart HCoresh J et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003;63 (3) 1121- 1129PubMedGoogle ScholarCrossref 3. Manjunath GTighiouart HIbrahim H et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003;41 (1) 47- 55PubMedGoogle ScholarCrossref 4. Muntner PHe JHamm LLoria CWhelton PK Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002;13 (3) 745- 753PubMedGoogle Scholar 5. Fried LFShlipak MGCrump C et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003;41 (8) 1364- 1372PubMedGoogle ScholarCrossref 6. Henry RMKostense PJBos G et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 2002;62 (4) 1402- 1407PubMedGoogle ScholarCrossref 7. Wattanakit KCoresh JMuntner PMarsh JFolsom AR Cardiovascular risk among adults with chronic kidney disease, with or without prior myocardial infarction. J Am Coll Cardiol 2006;48 (6) 1183- 1189PubMedGoogle ScholarCrossref 8. Levey ASBeto JACoronado BE et al. National Kidney Foundation Task Force on Cardiovascular Disease, Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? what do we need to learn? where do we go from here? Am J Kidney Dis 1998;32 (5) 853- 906PubMedGoogle ScholarCrossref 9. Sarnak MJLevey ASSchoolwerth AC et al. American Heart Association Councils on Kidney In Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention, Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney In Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108 (17) 2154- 2169PubMedGoogle ScholarCrossref 10. Collins AJKasiske BHerzog C et al. United States Renal Data System, Excerpts from the United States renal data system 2004 annual data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2005;45 (1) ((suppl 1)) A5- A7PubMedGoogle ScholarCrossref 11. DuBose TD Jr American Society of Nephrology presidential address 2006. Chronic kidney disease as a public health threat: new strategy for a growing problem. J Am Soc Nephrol 2007;18 (4) 1038- 1045PubMedGoogle ScholarCrossref 12. So WYKong APMa RC et al. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care 2006;29 (9) 2046- 2052PubMedGoogle ScholarCrossref 13. Brancati FLWhelton PKRandall BLNeaton JDStamler JKlag MJ Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 1997;278 (23) 2069- 2074PubMedGoogle ScholarCrossref 14. Brenner BM Brenner & Rector's the Kidney. 7th ed. Philadelphia, PA WB Saunders Co2004; 15. Kramer HJNguyen QDCurhan GHsu CY Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003;289 (24) 3273- 3277PubMedGoogle ScholarCrossref 16. Diabetes Control and Complications Research Group, Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial. Kidney Int 1995;47 (6) 1703- 1720PubMedGoogle ScholarCrossref 17. NHLBI Communications Office, For safety, NHLBI changes intensive blood sugar treatment strategy in clinical trial of diabetes and cardiovascular disease. http://public.nhlbi.nih.gov/newsroom/home/GetPressRelease.aspx?id=2551. Accessed February 13, 2008 18. ARIC Investigators, The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol 1989;129 (4) 687- 702PubMedGoogle Scholar 19. Papp ACHatzakis HBracey AWu KK ARIC hemostasis study: I, development of a blood collection and processing system suitable for multicenter hemostatic studies. Thromb Haemost 1989;61 (1) 15- 19PubMedGoogle Scholar 20. Little RR Glycated hemoglobin standardization: National Glycohemoglobin Standardization Program (NGSP) perspective. Clin Chem Lab Med 2003;41 (9) 1191- 1198PubMedGoogle ScholarCrossref 21. Selvin ECoresh JJordahl JBoland LSteffes MW Stability of haemoglobin A1c (HbA1c) measurements from frozen whole blood samples stored for over a decade. Diabet Med 2005;22 (12) 1726- 1730PubMedGoogle ScholarCrossref 22. Steffes MCleary PGoldstein D et al. Hemoglobin A1c measurements over nearly two decades: sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study. Clin Chem 2005;51 (4) 753- 758PubMedGoogle ScholarCrossref 23. Coresh JAstor BCMcQuillan G et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 2002;39 (5) 920- 929PubMedGoogle ScholarCrossref 24. Levey ASBosch JPLewis JBGreene TRogers NRoth DModification of Diet in Renal Disease study group, A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130 (6) 461- 470PubMedGoogle ScholarCrossref 25. Friedewald WTLevy RIFredrickson DS Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18 (6) 499- 502PubMedGoogle Scholar 26. Klein RSharrett ARKlein BE et al. ARIC Group, The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the Atherosclerosis Risk in Communities Study. Ophthalmology 2002;109 (7) 1225- 1234PubMedGoogle ScholarCrossref 27. Sharrett ARHubbard LDCooper LS et al. Retinal arteriolar diameters and elevated blood pressure. the Atherosclerosis Risk in Communities Study. Am J Epidemiol 1999;150 (3) 263- 270PubMedGoogle ScholarCrossref 28. Hubbard LDBrothers RJKing WN et al. Methods for evaluation of retinal microvascular abnormalities associated with hypertension/sclerosis in the Atherosclerosis Risk in Communities Study. Ophthalmology 1999;106 (12) 2269- 2280PubMedGoogle ScholarCrossref 29. Shoham DAVupputuri SDiez Roux AV et al. Kidney disease in life-course socioeconomic context: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2007;49 (2) 217- 226PubMedGoogle ScholarCrossref 30. American Diabetes Association, Standards of medical care in diabetes: 2007. Diabetes Care 2007;30 ((suppl 1)) S4- S41PubMedGoogle ScholarCrossref 31. Fox CSLarson MGLeip EPMeigs JBWilson PWLevy D Glycemic status and development of kidney disease: the Framingham Heart Study. Diabetes Care 2005;28 (10) 2436- 2440PubMedGoogle ScholarCrossref 32. Wali RKHenrich WL Chronic kidney disease: a risk factor for cardiovascular disease. Cardiol Clin 2005;23 (3) 343- 362PubMedGoogle ScholarCrossref 33. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354(9178):602]. Lancet 1998;352 (9131) 837- 853PubMedGoogle ScholarCrossref 34. Forbes JMFukami KCooper ME Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes 2007;115 (2) 69- 84PubMedGoogle ScholarCrossref 35. Burns KD Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 2000;36 (3) 449- 467PubMedGoogle ScholarCrossref 36. Zhang SLFilep JGHohman TCTang SSIngelfinger JRChan JS Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells. Kidney Int 1999;55 (2) 454- 464PubMedGoogle ScholarCrossref 37. Huebschmann AGRegensteiner JGVlassara HReusch JE Diabetes and advanced glycoxidation end products. Diabetes Care 2006;29 (6) 1420- 1432PubMedGoogle ScholarCrossref 38. Pistrosch FReissmann EWildbrett JKoehler CHanefeld M Relationship between diurnal blood pressure variation and diurnal blood glucose levels in type 2 diabetic patients. Am J Hypertens 2007;20 (5) 541- 545PubMedGoogle ScholarCrossref 39. Afsar BSezer SElsurer ROzdemir FN Is HOMA index a predictor of nocturnal nondipping in hypertensives with newly diagnosed type 2 diabetes mellitus? Blood Press Monit 2007;12 (3) 133- 139PubMedGoogle ScholarCrossref 40. Cuspidi CMeani SLonati L et al. Short-term reproducibility of a non-dipping pattern in type 2 diabetic hypertensive patients. J Hypertens 2006;24 (4) 647- 653PubMedGoogle ScholarCrossref 41. Darcan SGoksen DMir S et al. Alterations of blood pressure in type 1 diabetic children and adolescents. Pediatr Nephrol 2006;21 (5) 672- 676PubMedGoogle ScholarCrossref 42. Izzedine HLaunay-Vacher VDeray G Abnormal blood pressure circadian rhythm: a target organ damage? Int J Cardiol 2006;107 (3) 343- 349PubMedGoogle ScholarCrossref 43. Tamura KTsurumi YSakai M et al. A possible relationship of nocturnal blood pressure variability with coronary artery disease in diabetic nephropathy. Clin Exp Hypertens 2007;29 (1) 31- 42PubMedGoogle ScholarCrossref 44. Caramori MLFioretto PMauer M Enhancing the predictive value of urinary albumin for diabetic nephropathy [published correction appears in J Am Soc Nephrol. 2006 Apr;17(4):1201]. J Am Soc Nephrol 2006;17 (2) 339- 352PubMedGoogle ScholarCrossref 45. Wong TYKlein RAmirul Islam FM et al. Three-year incidence and cumulative prevalence of retinopathy: the Atherosclerosis Risk in Communities Study. Am J Ophthalmol 2007;143 (6) 970- 976PubMedGoogle ScholarCrossref

Journal

Archives of Internal Medicine – American Medical Association

Published: Dec 8, 2008

Keywords: diabetes mellitus,kidney failure, chronic,diabetes mellitus, type 2,hemoglobin a, glycosylated,retinal diseases,glycemic control, poor,aric trial,kidney diseases,hemoglobin,follow-up,glomerular filtration rate, estimated,glomerular filtration rate

There are no references for this article.